The first decision considering the scope and meaning of the provisions in the Patent Act relating to Certificates of Supplementary Protection (CSPs) has now been released. Justice Barnes of the Federal Court in...more
5/14/2020
/ Canada ,
Certificates of Supplementary Protection (CSPs) ,
CETA ,
EU ,
GlaxoSmithKline ,
Health Canada ,
Patent Act ,
Patent Litigation ,
Patented Medicines ,
Patents ,
Vaccinations
Bill C-30 was passed by the Senate yesterday, May 11, 2017 without amendment. Bill C-30 is the bill that will implement the Canada-European Union Comprehensive Economic and Trade Agreement (CETA). As reported here, this...more
After seven years of talks, delays and drama, changes to Canada’s intellectual property laws as a result of the nation’s free trade deal with the European Union are finally coming into view.
On Oct. 31, the federal...more
On October 31, 2016, the day following the signing of CETA, the Canadian Minister of International Trade, the Honourable Chrystia Freeland, tabled Bill C-30, An Act to implement the Comprehensive Economic and Trade Agreement...more
11/2/2016
/ Appeals ,
Canada ,
Canadian Patent Office ,
CETA ,
EU ,
Exports ,
Foreign Patent Applications ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Pharmaceutical Patents ,
Proposed Legislation ,
Supplementary Protection Certificate ,
Trade Agreements